文献速递肝病

GLP-1/胰高血糖素双受体激动剂pemvidutide对MASLD的影响:一项随机、双盲、安慰剂对照研究

Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
PubMed 文献 · J Hepatol · 2024-07-11

这项随机双盲安慰剂对照研究纳入94例BMI≥28.0 kg/m2且磁共振质子密度脂肪分数测得肝脂肪含量(LFC)≥10%的MASLD患者,按1:1:1:1随机接受pemvidutide 1.2 mg、1.8 mg、2.4 mg或安慰剂皮下注射每周一次共12周。第12周LFC相对降幅在各pemvidutide组分别为46.6%、68.5%、57.1%,安慰剂组为4.4%(所有治疗组vs安慰剂p<0.001)。

要点

  • 每周一次pemvidutide 12周使MASLD患者肝脂肪含量较安慰剂显著下降。
  • 1.8 mg剂量组94.4%和72.2%患者分别实现LFC降低30%和50%,55.6%实现LFC正常化(≤5%)。
  • 体重下降(-4.3%)、丙氨酸氨基转移酶(-13.8 IU/L)和校正cT1(-75.9 ms)的最大效应均见于1.8 mg剂量组。

核心结论

  • 在MASLD患者中,每周一次pemvidutide治疗较安慰剂显著降低肝脂肪含量、肝脏炎症标志物和体重。
  • 作者认为pemvidutide可能对代谢功能障碍相关脂肪性肝炎和肥胖均有效。

研究设计与样本

  • 随机、双盲、安慰剂对照研究。
  • 纳入BMI≥28.0 kg/m2且磁共振质子密度脂肪分数测得LFC≥10%的患者,按1:1:1:1随机接受pemvidutide 1.2 mg、1.8 mg、2.4 mg或安慰剂皮下注射每周一次共12周。
  • 按是否诊断2型糖尿病进行分层。
  • 共94例患者被随机并接受给药。
  • 主要疗效终点为治疗12周后LFC相对基线的降幅(%)。

主要发现

  • 研究人群基线BMI和LFC中位数分别为36.2 kg/m2和20.6%,29%的患者患有2型糖尿病。
  • 第12周LFC相对基线降幅:pemvidutide 1.2 mg组46.6%(95%CI -63.7至-29.6)、1.8 mg组68.5%(95%CI -84.4至-52.5)、2.4 mg组57.1%(95%CI -76.1至-38.1),安慰剂组4.4%(95%CI -20.2至11.3);所有治疗组vs安慰剂p<0.001。
  • 1.8 mg剂量组94.4%和72.2%的患者分别实现LFC降低30%和50%,55.6%实现LFC正常化(≤5%)。
  • 体重下降(-4.3%;p<0.001)、丙氨酸氨基转移酶(-13.8 IU/L;p=0.029)和校正cT1(-75.9 ms;p=0.002)的最大效应均见于1.8 mg剂量组。
  • pemvidutide在所有剂量下耐受良好,无严重或重度不良事件。

关键数值与推荐

  • 主要疗效终点为治疗12周后LFC相对基线的降幅(%)。
  • 入组标准为BMI≥28.0 kg/m2且磁共振质子密度脂肪分数测得LFC≥10%。
  • pemvidutide 1.2 mg、1.8 mg、2.4 mg或安慰剂皮下注射每周一次,共12周。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: This was a randomized, double-blind, placebo-controlled study to assess the effects of pemvidutide, a glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist, on liver fat content (LFC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: Patients with a BMI ≥28.0 kg/m2 and LFC ≥10% by magnetic resonance imaging-proton density fat fraction were randomized 1:1:1:1 to pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or placebo administered subcutaneously once weekly for 12 weeks. Participants were stratified according to a diagnosis of type 2 diabetes mellitus. The primary efficacy endpoint was relative reduction (%) from baseline in LFC after 12 weeks of treatment. RESULTS: Ninety-four patients were randomized and dosed. Median baseline BMI and LFC across the study population were 36.2 kg/m2 and 20.6%; 29% of patients had type 2 diabetes mellitus. At week 12, relative reductions in LFC from baseline were 46.6% (95% CI -63.7 to -29.6), 68.5% (95% CI -84.4 to -52.5), and 57.1% (95% CI -76.1 to -38.1) for the pemvidutide 1.2 mg, 1.8 mg, and 2.4 mg groups, respectively, vs. 4.4% (95% CI -20.2 to 11.3) for the placebo group (p <0.001 vs. placebo, all treatment groups), with 94.4% and 72.2% of patients achieving 30% and 50% reductions in LFC and 55.6% achieving normalization (≤5% LFC) at the 1.8 mg dose. Maximal responses for weight loss (-4.3%; p <0.001), alanine aminotransferase (-13.8 IU/L; p = 0.029), and corrected cT1 (-75.9 ms; p = 0.002) were all observed at the 1.8 mg dose. Pemvidutide was well-tolerated at all doses with no severe or serious adverse events. CONCLUSIONS: In patients with MASLD, weekly pemvidutide treatment yielded significant reductions in LFC, markers of hepatic inflammation, and body weight compared to placebo. IMPACT AND IMPLICATIONS: Metabolic dysfunction-associated steatotic liver disease, and its progressive form steatohepatitis, are strongly associated with overweight/obesity and it is believed that the excess liver fat associated with obesity is an important driver of these diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonists elicit weight loss through centrally and peripherally mediated effects on appetite. Unlike GLP-1R agonists, glucagon receptor agonists act directly on the liver to stimulate fatty acid oxidation and inhibit lipogenesis, potentially providing a more potent mechanism for liver fat content reduction than weight loss alone. This study demonstrated the ability of once-weekly treatment with pemvidutide, a dual GLP-1R/glucagon receptor agonist, to significantly reduce liver fat content, hepatic inflammatory activity, and body weight, suggesting that pemvidutide may be an effective treatment for both metabolic dysfunction-associated steatohepatitis and obesity. CLINICAL TRIAL NUMBER: NCT05006885.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2024. PMID: 39002641. doi:10.1016/j.jhep.2024.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。